Steven Buechler

This inventor holds 9 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: University of Notre Dame Du Lac, Indiana University. Active years: 2013-2023.

USPTO Granted Patents = 9 (Patent Applications = 2)

% Patents Active = 55.6

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 1.3

ph-index = 1

Forward Citations = 16(Granted Patents)

Company Filing History:

9 out of 385

University of Notre Dame Du Lac

where one patent can have more than one assignee

Years Active: 2013-2023

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11851713 - Assessing colorectal cancer molecular subtype and uses thereof (2023-12-26),

2. 11549152 - Products for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon (2023-01-10),

3. 11198911 - Systems and methods for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon (2021-12-14),

4. 10174382 - Breast cancer prognostication and screening kits and methods of using same (2019-01-08),

5. 10087489 - Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease (2018-10-02),

6. 9721067 - Accelerated progression relapse test (2017-08-01),

7. 9580756 - Stratification of left-side and right-side colon cancer (2017-02-28),

8. 9464328 - Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease (2016-10-11),

9. 8597885 - Accelerated progression relapse test (2013-12-03),

Title: Innovations in Colorectal Cancer Research by Steven Buechler

Introduction

Steven Buechler is an accomplished inventor based in Granger, IN (US), with a focus on advancements in colorectal cancer research. He holds a total of 9 patents, showcasing his commitment to improving cancer diagnostics and treatment protocols. His work has significant implications for the medical field, particularly in the classification and treatment of colon cancer.

Latest Patents

Buechler's latest patents include groundbreaking methods for assessing colorectal cancer molecular subtypes. One of his notable inventions involves genetic methods and tools for classifying colon cancer into distinct disease subtypes, namely CMS1, CMS2, CMS3, and CMS4. These innovations provide improved methods for rapid, accurate, and reproducible disease subtype determination. Additionally, tailored treatment protocols are developed based on the predicted CMS of the subject sample. His patents also encompass products and systems for classifying human colorectal cancer into a consensus molecular subtype and assessing the risk of recurrence based on CMS scores. These advancements aim to determine suitable treatment protocols for patients and enhance the overall effectiveness of cancer care.

Career Highlights

Throughout his career, Steven Buechler has made significant contributions to the field of cancer research. He has worked with prestigious institutions such as the University of Notre Dame Du Lac and Indiana University. His experience in these organizations has allowed him to collaborate with leading experts in the field and further his research endeavors.

Collaborations

Buechler has collaborated with notable colleagues, including Amanda B. Hummon and Sunil Badve. These partnerships have facilitated the exchange of ideas and expertise, contributing to the advancement of cancer research and treatment methodologies.

Conclusion

Steven Buechler's innovative work in colorectal cancer research has led to significant advancements in the classification and treatment of the disease. His contributions through patents and collaborations highlight his dedication to improving patient outcomes in the field of oncology.